Literature DB >> 19910674

Deletion of CFTR translation start site reveals functional isoforms of the protein in CF patients.

Anabela S Ramalho1, Marzena A Lewandowska, Carlos M Farinha, Filipa Mendes, Juan Gonçalves, Celeste Barreto, Ann Harris, Margarida D Amaral.   

Abstract

BACKGROUND/AIMS: Mutations in the CFTR gene cause Cystic Fibrosis (CF) the most common life-threatening autosomal recessive disease affecting Caucasians. We identified a CFTR mutation (c.120del23) abolishing the normal translation initiation codon, which occurs in two Portuguese CF patients. This study aims at functionally characterizing the effect of this novel mutation.
METHODS: RNA and protein techniques were applied to both native tissues from CF patients and recombinant cells expressing CFTR constructs to determine whether c.120del23 allows CFTR protein production through usage of alternative internal codons, and to characterize the putative truncated CFTR form(s).
RESULTS: Our data show that two shorter forms of CFTR protein are produced when the initiation translation codon is deleted indicating usage of internal initiation codons. The N-truncated CFTR generated by this mutation has decreased stability, very low processing efficiency, and drastically reduced function. Analysis of mutants of four methionine codons downstream to M1 (M82, M150, M152, M156) revealed that each of the codons M150/M152/M156 (exon 4) can mediate CFTR alternative translation.
CONCLUSIONS: The CFTR N-terminus has an important role in avoiding CFTR turnover and in rendering effective its plasma membrane traffic. These data correlate well with the severe clinical phenotype of CF patients bearing the c.120del23 mutation. 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910674      PMCID: PMC2793277          DOI: 10.1159/000257426

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  36 in total

Review 1.  Messenger RNA regulation: to translate or to degrade.

Authors:  Ann-Bin Shyu; Miles F Wilkinson; Ambro van Hoof
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

Review 2.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

Authors:  B J Rosenstein; G R Cutting
Journal:  J Pediatr       Date:  1998-04       Impact factor: 4.406

Review 3.  Processing of CFTR: traversing the cellular maze--how much CFTR needs to go through to avoid cystic fibrosis?

Authors:  Margarida D Amaral
Journal:  Pediatr Pulmonol       Date:  2005-06

4.  Phosphorylation-regulated Cl- channel in CHO cells stably expressing the cystic fibrosis gene.

Authors:  J A Tabcharani; X B Chang; J R Riordan; J W Hanrahan
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

5.  Direct comparison of the functional roles played by different transmembrane regions in the cystic fibrosis transmembrane conductance regulator chloride channel pore.

Authors:  Ning Ge; Chantal N Muise; Xiandi Gong; Paul Linsdell
Journal:  J Biol Chem       Date:  2004-10-25       Impact factor: 5.157

6.  Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation.

Authors:  Luísa S Pissarra; Carlos M Farinha; Zhe Xu; André Schmidt; Patrick H Thibodeau; Zhiwei Cai; Philip J Thomas; David N Sheppard; Margarida D Amaral
Journal:  Chem Biol       Date:  2008-01

7.  The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70.

Authors:  Carlos M Farinha; Paulo Nogueira; Filipa Mendes; Deborah Penque; Margarida D Amaral
Journal:  Biochem J       Date:  2002-09-15       Impact factor: 3.857

8.  Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene.

Authors:  R D Palmiter; R R Behringer; C J Quaife; F Maxwell; I H Maxwell; R L Brinster
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

9.  Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins.

Authors:  C L Ward; R R Kopito
Journal:  J Biol Chem       Date:  1994-10-14       Impact factor: 5.157

Review 10.  Pushing the limits of the scanning mechanism for initiation of translation.

Authors:  Marilyn Kozak
Journal:  Gene       Date:  2002-10-16       Impact factor: 3.688

View more
  13 in total

1.  Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis.

Authors:  Laia Masvidal; Susana Igreja; Maria D Ramos; Antoni Alvarez; Javier de Gracia; Anabela Ramalho; Margarida D Amaral; Sara Larriba; Teresa Casals
Journal:  Eur J Hum Genet       Date:  2013-10-16       Impact factor: 4.246

2.  A Common Polymorphism in HIBCH Influences Methylmalonic Acid Concentrations in Blood Independently of Cobalamin.

Authors:  Anne M Molloy; Faith Pangilinan; James L Mills; Barry Shane; Mary B O'Neill; David M McGaughey; Aneliya Velkova; Hatice Ozel Abaan; Per M Ueland; Helene McNulty; Mary Ward; J J Strain; Conal Cunningham; Miriam Casey; Cheryl D Cropp; Yoonhee Kim; Joan E Bailey-Wilson; Alexander F Wilson; Lawrence C Brody
Journal:  Am J Hum Genet       Date:  2016-04-28       Impact factor: 11.025

3.  Multiple mechanisms influence regulation of the cystic fibrosis transmembrane conductance regulator gene promoter.

Authors:  Marzena A Lewandowska; Fabricio F Costa; Jared M Bischof; Sarah H Williams; Marcelo B Soares; Ann Harris
Journal:  Am J Respir Cell Mol Biol       Date:  2009-10-23       Impact factor: 6.914

4.  Two novel compound heterozygous mutations in OPA3 in two siblings with OPA3-related 3-methylglutaconic aciduria.

Authors:  Christina Lam; Linda K Gallo; Richard Dineen; Carla Ciccone; Heidi Dorward; George E Hoganson; Lynne Wolfe; William A Gahl; Marjan Huizing
Journal:  Mol Genet Metab Rep       Date:  2014-01-01

5.  Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models.

Authors:  Jeffrey KiHyun Park; Anura Shrivastava; Chengkang Zhang; Brian A Pollok; Walter E Finkbeiner; Elizabeth R Gibb; Ngoc P Ly; Beate Illek
Journal:  Front Pediatr       Date:  2020-09-04       Impact factor: 3.418

6.  Positional effects of premature termination codons on the biochemical and biophysical properties of CFTR.

Authors:  Jiunn-Tyng Yeh; Tzyh-Chang Hwang
Journal:  J Physiol       Date:  2019-11-02       Impact factor: 5.182

7.  An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.

Authors:  Marzena Anna Lewandowska; Jacek Furtak; Tadeusz Szylberg; Krzysztof Roszkowski; Wiesława Windorbska; Joanna Rytlewska; Wojciech Jóźwicki
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

8.  Severe phenotype in an apparent homozygosity caused by a large deletion in the CFTR gene: a case report.

Authors:  Raisa da Silva Martins; Ana Carolina Proença Fonseca; Franklyn Enrique Samudio Acosta; Tania Wrobel Folescu; Laurinda Yoko Shinzato Higa; Izabela Rocha Sad; Célia Regina Moutinho de Miranda Chaves; Pedro Hernan Cabello; Giselda Maria Kalil Cabello
Journal:  BMC Res Notes       Date:  2014-08-30

9.  Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis.

Authors:  Neeraj Sharma; Taylor A Evans; Matthew J Pellicore; Emily Davis; Melis A Aksit; Allison F McCague; Anya T Joynt; Zhongzhu Lu; Sangwoo T Han; Arianna F Anzmann; Anh-Thu N Lam; Abigail Thaxton; Natalie West; Christian Merlo; Laura B Gottschalk; Karen S Raraigh; Patrick R Sosnay; Calvin U Cotton; Garry R Cutting
Journal:  PLoS Genet       Date:  2018-11-16       Impact factor: 5.917

Review 10.  A comprehensive overview of the cystic fibrosis on the island of São Miguel (Azores, Portugal).

Authors:  Joana Rosa; Patrícia Gaspar-Silva; Paula Pacheco; Conceição Silva; Cláudia C Branco; Barbara S Vieira; Alexandra Carreiro; Juan Gonçalves; Luisa Mota-Vieira
Journal:  BMC Pediatr       Date:  2020-01-03       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.